Genomic Profiling for Bladder Cancer
Decipher Bladder is the only genomic subtyping tool available to physicians in the United States treating patients with locally advanced bladder cancer.
in classifying bladder tumors into four molecular subtypes
genome-wide assay of 46,000 genes
model derived from the Cancer Genome Atlas project
Decipher Bladder accurately classifies the molecular subtype of muscle-invasive bladder cancer and informs which patients may benefit from neoadjuvant chemotherapy (NAC) prior to radical cystectomy.
Men and women considering NAC prior to surgery
Survival benefit from
NAC by molecular subtyping
Badrinath Konety, MD
University of Minnesota
“Decipher Bladder can reveal the biological nature of the patient’s tumor. It is the most promising tool we currently have available as a potential aid in clinical decision making prior to radical cystectomy.”
Physicians \ Order a Test
2. Fax the completed form, along with the pathology report and insurance information to:
Specimen Acceptance Criteria
Gleason 3+3 = 6
(PSA < 20 ng/mL)
Gleason 3+4 = 7
(all PSA values)
Surgical Margin Positive
(extraprostatic extension or
bladder neck invasion)
(seminal vesicle invasion)
(with 2 consecutive rises in PSA)
of Bladder Tumor)
Urothelial/Transitional Cell Muscle Invasive Carcinoma
Patients \ Insurance Information
Decipher Biosciences is committed to ensuring access for all patients.
Decipher Prostate is covered by Medicare, Medicare Advantage and select private insurers.
Through Decipher Assist, we offer programs designed to ensure testing is affordable for patients, including:
• Financial assistance for patients with demonstrated financial need
• Tailored payment plans to accommodate certain specific financial circumstances
For more information on the Decipher test and Decipher Assist, please contact the Decipher Assist team at:
888.792.1601 or download the Decipher Assist brochure.
Decipher Bladder is available on a self-pay basis. For more information, please contact the Decipher team at: